Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.

We report a phase I/II study of the indole derivative, zindoxifene, an anti-oestrogen with intrinsic oestrogenic activity. We have treated 28 women with advanced breast cancer of whom 26 had received prior endocrine therapy. Oral zindoxifene doses ranged from 10 to 100 mg daily; doses were escalated...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, R. C., Dowsett, M., Cunningham, D. C., Davenport, J., Ford, H. T., Gazet, J. C., von Angerer, E., Coombes, R. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971274/
https://www.ncbi.nlm.nih.gov/pubmed/2328214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971274/
https://www.ncbi.nlm.nih.gov/pubmed/2328214

Ejemplares similares